

## **Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.73 Billion in February**

### **保瑞公告 2 月自結合併營收新台幣 17 億 3 仟萬元**

Taipei, Taiwan, March 10, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for February 2025 reached NT\$1.73 billion, reflecting a 96.32% increase YoY.

台北，台灣，2025 年 3 月 10 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 2 月自結合併營收為新台幣 17 億 3 仟萬元，年增 96.32%。

During the month, Zhunan site saw an acceleration in the previously delayed tech transfer of new clients and the Maryland sterile injectable facility resumed full operations. However, certain generic portfolio of Upsher-Smith remains to be under pricing pressure. The Company is actively evaluating a phased discontinuation of these products, in compliance with existing supply agreements, to enhance its margin profile in the near term.

二月時竹南廠原先延遲的新客戶技術轉移進度已加快，美國馬里蘭的無菌針劑廠的產線亦全面恢復作業。然而，Upsher-Smith 部分學名藥產品仍持續面臨價格壓力，公司正積極評估在符合既有供應協議的前提下逐步停止相關產品的銷售，以期優化獲利結構。

Compared to the same period in 2024, the Canada site remained strong, supported by continued outsourcing from a heavy-weight client that relies on Bora as a trusted manufacturing partner. A key growth catalyst for our commercial business, Vigafyde oral solution, also continues to outperform. Overall, despite planned integration efforts in the first half of 2025, the Company remains confident and pleased with its progress in navigating this transformative new phase.

與 2024 年同期相比，加拿大廠持續展現穩健表現，受惠於重量級客戶持續委外生產，充分彰顯保瑞作為得信賴的製造夥伴的價值。而 Vigafyde 口服液銷售表現佳，持續為全球銷售業務的成長及轉型貢獻動能。整體而言，儘管 2025 年上半年有計劃中的整合工作須執行，公司對於當前的發展以及駕馭這一變革性的全新階段進度充滿信心。

**About Bora:**

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracorpcdmo.com>

**關於保瑞：**

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracorpcdmo.com>

**Investor/Media enquiries**

Nadiya Chen, Investor Relations

+886 2 790-1555 Ext. 9108

Email : [Nadiya.Chen@bora-corp.com](mailto:Nadiya.Chen@bora-corp.com)

**新聞聯繫人：**

投資人關係 陳荻雅

電話：(02) 2790-1555 #9108

Email : [Nadiya.Chen@bora-corp.com](mailto:Nadiya.Chen@bora-corp.com)